Mirus Bio receives ISO 13485:2016 certification, underscoring the quality of processes used to support GMP product portfolio. Read more

mirus bio logo
Search
Close this search box.

VirusGEN GMP AAV Transfection Kit

Proven Nucleic Acid Delivery for Large-Scale Virus Production

SKU MIR 6815-GMP Categories , ,

Description

TransIT-VirusGEN® GMP Transfection Reagent is designed to enhance delivery of packaging and transfer vector DNA to suspension and adherent HEK 293 cell types in order to increase production of recombinant lentivirus and adeno-associated virus (AAV). Key benefits of TransIT-VirusGEN® GMP Transfection Reagent include:

  • Performance – Efficient DNA delivery for large-scale production of high-titer viral vectors
  • Quality – GMP manufactured and tested for appearance, identity, sterility, endotoxin and mycoplasma
  • Flexibility – Compatible with different virus production platforms and repeat filtration
  • Animal Origin Free – Fully synthetic transfection reagent formulation
With industry-leading performance in high-titer virus manufacturing, TransIT-VirusGEN® GMP offers a simplified, cost-effective workflow, making it the superior choice for large-scale therapeutic virus production. Titers can be further increased with optimized enhancers included in the VirusGEN® AAV Transfection Kit and VirusGEN® GMP LV Transfection Kit.

For information on identity and residual reagent assays available through partner contract service laboratories, please contact techsupport@mirusbio.com.

Example Certificate of Analysis (PDF)

Example Certificate of Origin and BSE TSE Statement (PDF)

TransIT-VirusGEN® GMP is intended to be used as an ancillary material for cell, gene and tissue-engineered products, per USP <1043>.

SKU: MIR 6815-GMP

Supporting Data

 

 

TransIT-VirusGEN® Reagent and the VirusGEN® AAV Transfection Kit Generate Higher AAV Titers. (A) Expi293F™ cells (Thermo Fisher Scientific) grown in Expi293™ Expression Media (Thermo Fisher Scientific) were used to generate recombinant AAV2 via transient transfection using TransIT-VirusGEN® Transfection reagent (1.5:1 reagent-to-DNA ratio (vol:wt), Mirus Bio LLC), VirusGEN® AAV Transfection Kit (Mirus Bio LLC), Competitor A1 (1:1) or Competitor A3 (1:1) using their recommended protocol.  AAV2 was produced by transfecting pAAV-hrGFP, pAAV-RC and pAAV-Helper plasmids (1:1:1 DNA ratio, 2 μg/ml-2 mg per flask, Agilent Technologies). Cells were transfected at a cell density of 2 x 10cells/ml, 1 L in a 2.8 L Thomson shake flask. AAV2 was harvested at 72 hours post-transfection using chemical lysis. (A) Functional titers were determined via transduction of HT-1080 cells and GFP expression was measured 48 hours post-transduction using Guava® easyCyte™ 5HT Flow Cytometer. AAV functional titers were measured from virus dilutions with less than 20% GFP positive cells. Genome copies were determined by ddPCR using primers and a probe targeting the CMV promoter. (B) Total assembled capsids were determined using the AAV2 Titration ELISA Kit (Progen) and the GC/capsid ratio was determined by dividing the number of genome copies by total assembled capsids for each condition. The error bars represent the range of duplicate flasks.

 

TransIT-VirusGEN® Reagent and the VirusGEN® AAV Transfection Kit Outperform PEI-based Reagents for AAV Production across Different Suspension Cell Types and Media Formulations. (A) Expi293F™ cells (Thermo Fisher Scientific) or (B) Viral Production cells (Thermo Fisher Scientific) were grown or adapted to Expi293™ Media (Thermo Fisher Scientific), LV-MAX™ Production (Thermo Fisher Scientific), FreeStyle™ F17 (Thermo Fisher Scientific), or BalanCD HEK293 (Irvine Scientific) media prior to transfection. AAV production using TransIT-VirusGEN® Transfection reagent (2:1 reagent-to-DNA ratio (vol:wt), Mirus Bio LLC), VirusGEN® AAV Transfection Kit (Mirus Bio LLC) was compared to Competitor A3 (1:1 reagent-to-DNA ratio (vol:wt)) and Competitor C1 (2:1 reagent-to-DNA ratio (vol:wt)) using their recommended protocol. AAV2 was produced by transfecting pAAV-hrGFP, pAAV-RC, and pAAV-Helper plasmids (1:1:1 DNA ratio, 1.5 μg/ml = 3 μg/well, Agilent Technologies). Cells were transfected at a cell density of 2 million cells/ml. Harvested virus was used to transduce HT1080 cells and GFP expression was measured 48 hours post-transduction using Guava® easyCyte™ 5HT Flow Cytometer. AAV functional titers were measured from virus dilutions with less than 20% GFP positive cells. The error bars represent the range of duplicate wells.

Resources

Specifications

Storage Conditions:
VirusGEN® GMP AAV Complex Formation Solution and Enhancer: Store at 2 to 10°C
VirusGEN® GMP AAV Transfection Kit: Multiple storage conditions – see individual bottles for specific recommendations
TransIT-VirusGEN® GMP Transfection Reagent: Store at -10 to -30°C

Product Guarantee:
All Configurations: Refer to Certificate of Analysis for Retest Date

Usage Statement:
All Configurations: For Research Use and Further Manufacturing; Not for Administration into Humans.

Animal Origin Statement:
All Configurations: This product is animal origin free.

Technical Product Literature

Full Protocol
TransIT-VirusGEN® GMP Protocol (PDF)
VirusGEN® GMP AAV Transfection Kit Protocol (PDF)

SDS
TransIT-VirusGEN® GMP SDS (PDF)
VirusGEN® GMP AAV Complex Formation Solution and Enhancer SDS (PDF)
VirusGEN® GMP AAV Transfection Kit SDS (PDF)

Additional Resources

For a lot-specific Certificate of Analysis (COA) or Certificate of Origin (COO) containing a TSE/BSE Statement for this product, please contact techsupport@mirusbio.com.

FAQs

See the VirusGEN AAV FAQs

Using transfection reagents and enhancers from Mirus has given our platform a competitive advantage. Increasing efficiency and lowering costs for all of our porgrams.

 

Sally Mader, PhD
ZYZ Theraputics